Bide Pharmatech (SH:688073) Xin Lang Cai Jing·2025-09-09 02:16Core Viewpoint - Bid Pharma's stock price has shown a year-to-date increase of 33.56%, but has recently experienced a decline of 4.59% over the past five trading days, indicating volatility in its performance [1]. Company Overview - Bid Pharma, established on April 27, 2007, and listed on October 11, 2022, is located in Yangpu District, Shanghai. The company focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1]. - The company's main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1]. Financial Performance - For the first half of 2025, Bid Pharma achieved an operating income of 628 million yuan, representing a year-on-year growth of 17.91%. The net profit attributable to shareholders was 73.41 million yuan, reflecting a year-on-year increase of 41.60% [2]. - Since its A-share listing, Bid Pharma has distributed a total of 258 million yuan in dividends [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders for Bid Pharma increased by 4.76% to 3,782, while the average circulating shares per person decreased by 4.55% to 11,431 shares [2]. - Among the top ten circulating shareholders, notable changes include: - China Europe Medical Health Mixed A (003095) as the second-largest shareholder, holding 4.2526 million shares, down by 193,100 shares from the previous period - Agricultural Bank of China Medical Health Stock (000913) as the fourth-largest shareholder, holding 841,000 shares, up by 177,500 shares - New entrants include Guangfa Xinxing Mixed A (002132) and Changxin Jinli Trend Mixed A (519994) [3].